Hydroxycarbamide: Difference between revisions

{{Short description|Medication}}

{{Use dmy dates|date=May 2024}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{Infobox drug

| Watchedfields = changed

| verifiedrevid = 458281479

| image = Hydroxyurea.svg

| width = 140

| width2 =

| alt2 =

| caption =

| USAN = Hydroxyurea

<!-- Clinical data -->

| pronounce =

| tradename = Droxia, Hydrea, Siklos, others

| Drugs.com = {{drugs.com|monograph|hydroxyurea}}

| DailyMedID = Hydroxyurea

| pregnancy_AU = D

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration = [[Oral administration|By mouth]]

| class =

| ATC_prefix = L01

| ATC_suffix = XX05

| ATC_supplemental =

<!-- Legal status -->

| legal_AU = S4

| legal_AU_comment =

| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->

| legal_BR_comment =

| legal_CA = Rx-only

| legal_CA_comment =

| legal_DE = <!-- Anlage I, II, III or Unscheduled -->

| legal_DE_comment =

| legal_NZ = <!-- Class A, B, C -->

| legal_NZ_comment =

| legal_UK = POM

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = <ref>{{cite web | title=Xromi- hydroxyurea solution | website=DailyMed | date=8 April 2024 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b37d336-86da-4363-aef1-34a7d3ba973b | access-date=18 May 2024}}</ref>

| legal_EU = Rx-only

| legal_EU_comment = <ref name="Siklos EPAR">{{cite web | title=Siklos EPAR | website=European Medicines Agency | date=9 July 2003 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/siklos | access-date=24 July 2024}}</ref>

| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->

| legal_UN_comment =

| legal_status = Rx-only

<!-- Pharmacokinetic data -->

| bioavailability =

| protein_bound =

| metabolism = [[Liver]] (to CO2 and urea)

| metabolites =

| onset =

| elimination_half-life = 2–4 hours

| duration_of_action =

| excretion = [[Kidney]] and lungs

<!-- Identifiers -->

| CAS_supplemental =

| IUPHAR_ligand = 6822

| NIAID_ChemDB = 006310

| PDB_ligand =

| synonyms =

<!-- Chemical and physical data -->

| IUPAC_name = Hydroxyurea

| C=1 | H=4 | N=2 | O=2

| SMILES = O=C(N)NO

| StdInChI_comment =

| density =

| density_notes =

| melting_point = 133

| melting_high = 136

| melting_notes =

| boiling_point =

| boiling_notes =

| solubility =

| sol_units =

| specific_rotation =

<!-- Definition and medical uses -->

'''Hydroxycarbamide''', also known as '''hydroxyurea''', is a medication used in [[sickle-cell disease]], [[essential thrombocythemia]], [[chronic myelogenous leukemia]], [[polycythemia vera]], and [[cervical cancer]].<ref name=AHFS2016/><ref name=UK2016>{{cite web|title=Hydrea 500 mg Hard Capsules – Summary of Product Characteristics (SPC) – (eMC)|url=https://www.medicines.org.uk/emc/medicine/19081|website=www.medicines.org.uk|access-date=14 December 2016|url-status=live|archive-url=https://web.archive.org/web/20161220184353/https://www.medicines.org.uk/emc/medicine/19081|archive-date=20 December 2016}}</ref> In sickle-cell disease it increases [[fetal hemoglobin]] and decreases the number of attacks.<ref name=AHFS2016/> It is taken by mouth.<ref name=AHFS2016/>

<!-- Side effects and mechanism -->

Common [[side effect]]s include [[bone marrow suppression]], fevers, loss of appetite, [[psychiatric problems]], [[shortness of breath]], and [[headache]]s.<ref name=AHFS2016/><ref name=UK2016/> There is also concern that it increases the risk of later [[cancer]]s.<ref name=AHFS2016/> Use during [[pregnancy]] is typically harmful to the fetus.<ref name=AHFS2016/> Hydroxycarbamide is in the [[antineoplastic]] family of medications.<!-- <ref name=AHFS2016 --> It is believed to work by blocking the making of [[DNA]].<ref name=AHFS2016/>

<!-- Society and culture -->

Hydroxycarbamide was approved for medical use in the United States in 1967.<ref name=AHFS2016>{{cite web|title=Hydroxyurea|url=https://www.drugs.com/monograph/hydroxyurea.html|publisher=The American Society of Health-System Pharmacists|access-date= 8 December 2016}}</ref> It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].<ref name="WHO21st">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 21st list 2019 | year = 2019 | hdl = 10665/325771 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO | hdl-access=free }}</ref> Hydroxycarbamide is available as a [[generic medication]].<ref name=AHFS2016/>

==Medical uses==

Hydroxycarbamide is used for the following [[Indication (medicine)|indications]]:

* [[Myeloproliferative disease]] (primarily [[essential thrombocythemia]] and [[polycythemia vera]]). It has been found to be superior to [[anagrelide]] for the control of ET.<ref name="pmid16000354">{{cite journal | vauthors = Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR | title = Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia | journal = The New England Journal of Medicine | volume = 353 | issue = 1 | pages = 33–45 | date = July 2005 | pmid = 16000354 | doi = 10.1056/NEJMoa043800 | doi-access = free }}</ref>

* [[Sickle-cell disease]]<ref name="pmid18458272">{{cite journal | vauthors = Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB | title = Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease | journal = Annals of Internal Medicine | volume = 148 | issue = 12 | pages = 939–955 | date = June 2008 | pmid = 18458272 | pmc = 3256736 | doi = 10.7326/0003-4819-148-12-200806170-00221 }}</ref> (increases production of [[fetal hemoglobin]] that then interferes with the hemoglobin polymerisation as well as by reducing white blood cells that contribute to the general inflammatory state in sickle cell patients.)

* Second line treatment for [[psoriasis]]<ref name="pmid17642550">{{cite journal | vauthors = Sharma VK, Dutta B, Ramam M | title = Hydroxyurea as an alternative therapy for psoriasis | journal = Indian Journal of Dermatology, Venereology and Leprology | volume = 70 | issue = 1 | pages = 13–17 | year = 2004 | pmid = 17642550 | url = http://www.ijdvl.com/article.asp?issn=0378-6323;year=2004;volume=70;issue=1;spage=13;epage=17;aulast=Sharma | url-status = live | archive-url = https://web.archive.org/web/20090703155748/http://www.ijdvl.com/article.asp?issn=0378-6323%3Byear%3D2004%3Bvolume%3D70%3Bissue%3D1%3Bspage%3D13%3Bepage%3D17%3Baulast%3DSharma | archive-date = 3 July 2009 }}</ref> (slows down the rapid division of skin cells)

* [[Systemic mastocytosis]] with associated hematological neoplasm(SM-AHN) <ref>{{cite journal | vauthors = Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A | title = Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine | journal = American Journal of Hematology | volume = 84 | issue = 12 | pages = 790–794 | date = December 2009 | pmid = 19890907 | doi = 10.1002/ajh.21561 }}</ref> (The utility in treating SM-AHN with hydroxycarbamide stems from its myelosuppressive activity, it does not however exhibit any selective anti-[[mast cell]] activity)

* [[Chronic myelogenous leukemia]] (largely replaced by [[imatinib]], but still in use for its cost-effectiveness)<ref>{{cite journal | vauthors = Dalziel K, Round A, Stein K, Garside R, Price A | title = Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis | journal = Health Technology Assessment | volume = 8 | issue = 28 | pages = iii, 1-iii120 | date = July 2004 | pmid = 15245690 | doi = 10.3310/hta8280 | doi-access = free }}</ref>

Reported side effects are: [[neurological]] reactions (e.g., [[headache]], [[dizziness]], [[drowsiness]], [[disorientation]], [[hallucination]]s, and [[convulsion]]s), [[nausea]], [[vomiting]], [[diarrhea]], [[constipation]], [[mucositis]], [[anorexia (symptom)|anorexia]], [[stomatitis]], [[bone marrow toxicity]] (dose-limiting toxicity; may take 7–21 days to recover after the drug has been discontinued), [[megaloblastic anemia]], [[thrombocytopenia]], [[bleeding]], [[hemorrhage]], [[peptic ulcer disease|gastrointestinal ulceration]] and [[gastrointestinal perforation|perforation]], [[immunosuppression]], [[leukopenia]], [[alopecia]] (hair loss), [[skin rashes]] (e.g., [[maculopapular rash]]), [[erythema]], [[pruritus]], [[vesication]] or [[irritation]] of the [[skin]] and [[mucous membranes]], [[pulmonary edema]], abnormal [[liver enzyme]]s, [[creatinine]] and [[blood urea nitrogen]].<ref name=Liebelt2007>{{cite journal | vauthors = Liebelt EL, Balk SJ, Faber W, Fisher JW, Hughes CL, Lanzkron SM, Lewis KM, Marchetti F, Mehendale HM, Rogers JM, Shad AT, Skalko RG, Stanek EJ | title = NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea | journal = Birth Defects Research. Part B, Developmental and Reproductive Toxicology | volume = 80 | issue = 4 | pages = 259–366 | date = August 2007 | pmid = 17712860 | doi = 10.1002/bdrb.20123 }}</ref>

Due to its negative effect on the bone marrow, regular monitoring of the [[full blood count]] is vital, as well as early response to possible infections. In addition, [[renal function]], [[uric acid]] and [[electrolyte]]s, as well as [[liver enzyme]]s, are commonly checked.<ref name="gale">{{Cite book | vauthors = Longe JL |title=Gale Encyclopedia Of Cancer: A Guide To Cancer And Its Treatments |publisher=Thomson Gale |location=Detroit |year=2002 |pages=[https://archive.org/details/galeencyclopedia0000unse_b0o7/page/514 514–516] |isbn=978-1-4144-0362-5 |url-access=registration |url=https://archive.org/details/galeencyclopedia0000unse_b0o7/page/514 }}</ref> Moreover, because of this, its use in people with leukopenia, thrombocytopenia or severe [[anemia]] is contraindicated.<ref>{{cite web |title=HYDREA |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/016295s040lbl.pdf |website=Accessdata.fda.gov |publisher=US Food and Drug Administration}}</ref>

==Mechanism of action==

Hydroxycarbamide decreases the production of [[deoxyribonucleotide]]s<ref>{{DorlandsDict|four/000050608|hydroxyurea}}</ref> via inhibition of the enzyme [[ribonucleotide reductase]] by scavenging tyrosyl free radicals as they are involved in the reduction of nucleoside diphosphates (NDPs).<ref name=Platt2008>{{cite journal | vauthors = Platt OS | title = Hydroxyurea for the treatment of sickle cell anemia | journal = The New England Journal of Medicine | volume = 358 | issue = 13 | pages = 1362–1369 | date = March 2008 | pmid = 18367739 | doi = 10.1056/NEJMct0708272 }}</ref>

In the treatment of [[sickle-cell disease]], hydroxycarbamide increases the concentration of [[fetal hemoglobin]]. The precise mechanism of action is not yet clear, but it appears that hydroxycarbamide increases [[nitric oxide]] levels, causing soluble [[guanylyl cyclase]] activation with a resultant rise in [[cyclic GMP]], and the activation of gamma globin gene expression and subsequent gamma chain synthesis necessary for fetal hemoglobin (HbF) production (which does not polymerize and deform red blood cells like the mutated HbS, responsible for sickle cell disease). Adult red cells containing more than 1% HbF are termed F cells. These cells are progeny of a small pool of immature committed erythroid precursors (BFU-e) that retain the ability to produce HbF. Hydroxyurea also suppresses the production of granulocytes in the bone marrow which has a mild immunosuppressive effect particularly at vascular sites where sickle cells have occluded blood flow.<ref name=Platt2008/><ref name="pmid12531879">{{cite journal | vauthors = Cokic VP, Smith RD, Beleslin-Cokic BB, Njoroge JM, Miller JL, Gladwin MT, Schechter AN | title = Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase | journal = The Journal of Clinical Investigation | volume = 111 | issue = 2 | pages = 231–239 | date = January 2003 | pmid = 12531879 | pmc = 151872 | doi = 10.1172/JCI16672 }}</ref>

==Natural occurrence==

Hydroxyurea has been reported as endogenous in human blood plasma at concentrations of approximately 30 to 200&nbsp;ng/ml.<ref>{{cite journal | vauthors = Kettani T, Cotton F, Gulbis B, Ferster A, Kumps A | title = Plasma hydroxyurea determined by gas chromatography-mass spectrometry | journal = Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences | volume = 877 | issue = 4 | pages = 446–450 | date = February 2009 | pmid = 19144580 | doi = 10.1016/j.jchromb.2008.12.048 }}</ref>

==Chemistry==

{{chembox

|container_only = yes

| Section7 = {{Chembox Hazards

| MainHazards = [[Mutagen]] – [[Reproductive toxicity]]

| GHSPictograms = {{GHS08}}

| GHSSignalWord = Danger

| HPhrases = {{H-phrases|340|361}}

| PPhrases = {{P-phrases|201|202|281|308+313|405|501}}}}

}}

Hydroxyurea has been prepared in many different ways since its initial synthesis in 1869.<ref name="Dresler and Stein et al 1869">{{cite journal| title=Ueber den Hydroxylharnstoff| vauthors = Dresler WF, Stein R |year=1869|journal=Justus Liebigs Ann. Chem. |volume=150 |issue=2|pages=1317–22|doi=10.1002/jlac.18691500212|url=https://zenodo.org/record/1663584}}</ref> The original synthesis by Dresler and Stein was based around the reaction of [[hydroxylamine hydrochloride]] and [[potassium cyanate]].<ref name="Dresler and Stein et al 1869" /> Hydroxyurea lay dormant for more than fifty years until it was studied as part of an investigation into the toxicity of protein metabolites.<ref name="PMC3069221">{{cite journal | vauthors = Rees DC | title = The rationale for using hydroxycarbamide in the treatment of sickle cell disease | journal = Haematologica | volume = 96 | issue = 4 | pages = 488–491 | date = April 2011 | pmid = 21454878 | pmc = 3069221 | doi = 10.3324/haematol.2011.041988 }}</ref> Due to its chemical properties hydroxyurea was explored as an antisickling agent in the treatment of hematological conditions.

One common mechanism for synthesizing hydroxyurea is by the reaction of calcium cyanate with hydroxylamine nitrate in absolute ethanol and by the reaction of a cyanate salt and hydroxylamine hydrochloride in aqueous solution.<ref name = "Hydroxyurea synthesis">{{cite patent| title = Synthesis of Ureas| year = 1955| inventor = Graham PJ | assign1 = E.I. du Pont de Nemours & Co., Wilmington, DE | country = US | number = 2705727 }}</ref> Hydroxyurea has also been prepared by converting a quaternary ammonium anion exchange resin from the chloride form to the cyanate form with sodium cyanate and reacting the resin in the cyanate form with hydroxylamine hydrochloride. This method of hydroxyurea synthesis was patented by Hussain et al. (2015).<ref name="Hussain et al 2016">{{cite journal|title=New Method for Synthesis of Hydroxyurea and Some of its Polymer Supported Derivatives As New Controlled Release Drugs|vauthors=Hussain KA, Abid DS, Adam GA| doi= 10.13140/RG.2.1.3607.2720|year=2016|journal=Journal of Basrah Research|volume=41|issue=1}}</ref>

==Pharmacology==

Hydroxyurea is a monohydroxyl-substituted urea (hydroxycarbamate) [[antimetabolite]]. Similar to other antimetabolite anti-cancer drugs, it acts by disrupting the DNA replication process of dividing cancer cells in the body. Hydroxyurea selectively inhibits [[ribonucleoside diphosphate reductase]], an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the [[G1/S transition|G1/S phase]] of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair.<ref name=pubchem>{{cite web | title=Hydroxyurea| work = PubChem | publisher = U.S. National Library of Medicine |url=https://pubchem.ncbi.nlm.nih.gov/compound/hydroxyurea#section=Prescription-Drug-Products|url-status=live|archive-url=https://web.archive.org/web/20170518234727/https://pubchem.ncbi.nlm.nih.gov/compound/hydroxyurea#section=Prescription-Drug-Products|archive-date=18 May 2017}}</ref>

Biochemical research has explored its role as a [[DNA replication]] inhibitor<ref name="pmid14573610">{{cite journal | vauthors = Koç A, Wheeler LJ, Mathews CK, Merrill GF | title = Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools | journal = The Journal of Biological Chemistry | volume = 279 | issue = 1 | pages = 223–230 | date = January 2004 | pmid = 14573610 | doi = 10.1074/jbc.M303952200 | s2cid = 2675195 | doi-access = free }}{{Dead link|date=February 2022 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> which causes deoxyribonucleotide depletion and results in DNA double strand breaks near [[replication fork]]s (see [[DNA repair]]). Repair of DNA damaged by chemicals or irradiation is also inhibited by hydroxyurea, offering potential synergy between hydroxyurea and radiation or alkylating agents.<ref name=pmid1641648>{{cite journal | vauthors = Yarbro JW | title = Mechanism of action of hydroxyurea | journal = Seminars in Oncology | volume = 19 | issue = 3 Suppl 9 | pages = 1–10 | date = June 1992 | pmid = 1641648 }}</ref>

Hydroxyurea has many pharmacological applications under the [[Medical Subject Headings]] classification system:<ref name="pubchem"/>

* Antineoplastic agents – Substances that inhibit or prevent the proliferation of neoplasms.

* Antisickling agents – Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions.

* Nucleic acid synthesis inhibitors – Compounds that inhibit cell production of DNA or RNA.

* Enzyme inhibitors – Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.

* Cytochrome P-450 [[CYP2D6]] inhibitors – Agents that inhibit one of the most important enzymes involved in the metabolism of xenobiotics in the body, [[CYP2D6]], a member of the cytochrome P450 mixed oxidase system.

== Society and culture ==

===Brand names===

Brand names include: Hydrea, Litalir, Droxia, and Siklos.{{citation needed|date=June 2020}}

== References ==

{{reflist}}

{{Portal bar | Medicine}}

{{Authority control}}

[[Category:Drugs developed by Bristol Myers Squibb]]

[[Category:IARC Group 3 carcinogens]]

[[Category:Wikipedia medicine articles ready to translate]]

[[Category:Sickle-cell disease]]

[[Category:Ureas]]

[[Category:World Health Organization essential medicines]]

[[Category:Multiple Chemboxes|X]]